This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
HOTH Stock Soars as Skin Toxicity Study in Cancer Patients Meets Goal
by Zacks Equity Research
Hoth stock soars as a mid-stage study meets the goal, showing significant improvement in skin toxicities related to EFGR inhibitor therapy in all HT-001-treated patients.
All You Need to Know About CytomX Therapeutics (CTMX) Rating Upgrade to Strong Buy
by Zacks Equity Research
CytomX Therapeutics (CTMX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
GSK's ADC Drug Gets FDA's Breakthrough Tag for Rare Bone Cancer
by Zacks Equity Research
The FDA bestows a Breakthrough Therapy designation to GSK's antibody-drug conjugate, GSK5764227, for treating relapsed or refractory osteosarcoma.
KOD Stock Rallies 271% in 6 Months on Eye Disease Program Updates
by Zacks Equity Research
Kodiak stock skyrockets 271% in six months on the back of positive updates from the tarcocimab program for treating retinal vascular diseases.
Here's Why Arcutis Stock More Than Doubled in Market Value in One Year
by Zacks Equity Research
The rally in ARQT's stock could be attributed to the encouraging regulatory updates seeking label expansion for its sole marketed drug.
MESO Stock Surges 80% in a Month After FDA Approval of GVHD Drug
by Zacks Equity Research
Mesoblast stock climbs 80% in a month following the FDA's approval of Ryoncil as the only approved therapy for SR-aGVHD in children aged two months and older.
CAPR Stock Up on Completion of Rolling Submission of DMD Drug BLA
by Zacks Equity Research
Capricor stock gains 8% upon completing the rolling submission of the BLA for its lead asset, deramiocel, to treat DMD cardiomyopathy in the United States.
Neumora Stock Hits Record Low on Depression Drug Study Failure
by Zacks Equity Research
NMRA stock falls after its experimental depression treatment failed to meet the primary and secondary endpoints in the first of three late-stage studies.
PGEN Stock Surges More Than 40% in a Week: What's Driving the Rally?
by Zacks Equity Research
The upside in Precigen's stock comes after it completes the rolling submission of an FDA filing for its first potentially marketed product.
VSTM Up as NDA for Ovarian Cancer Combo Gets FDA's Priority Review Tag
by Zacks Equity Research
The FDA accepts Verastem's NDA for the accelerated approval of avutometinib to treat recurrent KRAS mutant ovarian cancer under priority review. The stock rises 41%.
JNJ Inks Licensing Deal With Kaken for Eczema Candidate KP-723
by Zacks Equity Research
Johnson & Johnson announces a global licensing deal with Kaken for the latter's eczema candidate, KP-723, to further strengthen its dermatology portfolio.
MindMed Stock Skyrockets 94% Year to Date: What's Driving It?
by Zacks Equity Research
2024 was a transformational year for MNMD as it executed many important milestones.
Vertex Secures FDA Approval for New Cystic Fibrosis Drug Alyftrek
by Zacks Equity Research
The FDA's nod is based on late-stage data, which show that treatment with VRTX's Alyftrek enhances patient benefit compared to the blockbuster drug Trikafta.
AZN's Tagrisso Gets Approval in the EU for Expanded Use in NSCLC
by Zacks Equity Research
AstraZeneca wins approval in the EU for the label expansion of Tagrisso to treat adult patients with locally advanced, unresectable NSCLC.
RARE Submits BLA to the FDA for Sanfilippo Syndrome Gene Therapy
by Zacks Equity Research
Ultragenyx submits a BLA to the FDA seeking the accelerated approval of UX111 for patients with Sanfilippo syndrome type A in the United States.
VRTX Down as Non-Opioid Drug Shows Similar Pain Reduction as Placebo
by Zacks Equity Research
Vertex announces data from a phase II study evaluating its NaV1.8 pain signal inhibitor, suzetrigine, for treating painful lumbosacral radiculopathy. Shares down.
KRYS Reports Upbeat Initial Data From Lung Cancer Study of KB707
by Zacks Equity Research
Krystal Biotech reports initial data from a phase I/II study showing therapeutic benefit in NSCLC patients treated with its immunotherapy candidate, KB707.
SRPT Finishes Enrolment in Late-Stage Study for Rare Muscular Disorder
by Zacks Equity Research
The phase III EMERGENE study evaluates Sarepta's experimental gene therapy for an ultra-rare form of muscle disorder for which there is no treatment beyond symptom management.
GILD's Trodelvy Gets Second Breakthrough Therapy Tag for Lung Cancer
by Zacks Equity Research
Gilead announces that the FDA grants a second Breakthrough Therapy designation to Trodelvy for the extensive-stage small cell lung cancer indication.
EWTX Stock Rises on Upbeat Data From Rare Muscular Disorder Study
by Zacks Equity Research
Data from a mid-stage study show that treatment with Edgewise's experimental drug reduces levels of a biomarker related to skeletal muscle damage.
Merck Ends Development of Two Experimental Cancer Drugs
by Zacks Equity Research
MRK's decision to discontinue the development of two cancer drugs follows a series of setbacks in multiple late-stage studies.
CHMP Endorses Merck's Kidney Cancer Drug for Two Indications
by Zacks Equity Research
The CHMP's opinion is based on positive results from two late-stage studies on MRK's Welireg in two indications associated with renal cell carcinoma.
EDIT Stock Falls on Decision to End Reni-Cel Studies, Cut Workforce
by Zacks Equity Research
Editas stock falls as it ends development of reni-cel for SCD and TDT following failed attempts to find a commercial partner. It plans to cut workforce by 65%.
CytomX Therapeutics (CTMX) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
by Zacks Equity Research
CytomX Therapeutics (CTMX) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
ABBV to Acquire Nimble Therapeutics to Strengthen Immunology Pipeline
by Zacks Equity Research
AbbVie is set to acquire privately held biotech, Nimble Therapeutics, for $200 million to strengthen its immunology pipeline.